Document is current
Any future updates will be listed below
-
Authors
Sørensen, Anne Sofie
Andersen, Morten Nørgaard
Juul-Madsen, Kristian
Broksø, Amalie Dyrelund
Skejø, Cæcilie
Schmidt, Henrik
Vorup-Jensen, Thomas
Kragstrup, Tue Wenzel http://orcid.org/0000-0002-6439-397X
-
Funding
Funding for this research was provided by:
Det Frie Forskningsråd (9039-00015B)
Gigtforeningen
Kræftens Bekæmpelse
- License Information
-
More Information
Article History
Received: 16 August 2021
Accepted: 3 February 2022
First Online: 14 February 2022
Declarations
:
: All samples were obtained after informed written consent according to the declaration of Helsinki and approved by the Local Ethics committee (Central Denmark Region, project number: 20121329) and the Danish Data Protection Agency.
: TWK has engaged in educational activities presenting in topics on immunology in rheumatic diseases receiving speaking fees from Pfizer, Bristol-Myers Squibb, Eli Lilly, Novartis, and UCB and has received a consultancy fee from Bristol-Myers Squibb. TWK is co-founder and clinical developer in iBiotech ApS developing diagnostic and therapeutic solutions for people with autoimmune diseases and cancer. TV-J taught in a training course for health care professionals on the side effects of ICIs and was paid an honorarium by Roche. The rest of the authors declare no potential conflicts of interest.
